CSPC Pharmaceutical Group Ltd (NASDAQ:CHPTY) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Thursday.

According to Zacks, “CSPC Pharmaceutical Group Limited operates as a pharmaceutical group in China. Its bulk drug products include vitamin C, penicillin G and 7-ACA. The Company is also a major manufacturer of antibiotic finished drugs such as penicillin and cephalosporin products. CSPC Pharmaceutical Group Limited, formerly known as China Pharmaceutical Group Limited, is based in Wan Chai, Hong Kong. “

Shares of CSPC Pharmaceutical Group (NASDAQ CHPTY) remained flat at $73.27 during trading on Thursday. The company has a market capitalization of $8.87 billion and a PE ratio of 29.31. The firm has a 50 day moving average of $73.27 and a 200-day moving average of $67.98. CSPC Pharmaceutical Group has a 12 month low of $48.25 and a 12 month high of $73.36.

TRADEMARK VIOLATION NOTICE: “Zacks Investment Research Upgrades CSPC Pharmaceutical Group Ltd (CHPTY) to Hold” was originally posted by Watch List News and is the sole property of of Watch List News. If you are reading this piece on another publication, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be viewed at https://www.watchlistnews.com/zacks-investment-research-upgrades-cspc-pharmaceutical-group-ltd-chpty-to-hold/1534888.html.

About CSPC Pharmaceutical Group

CSPC Pharmaceutical Group Limited is an investment holding company principally engaged in the manufacture and sales of pharmaceutical products. The Company sells its products under the brand of CSPS. The Company has four business segments: Finished Drugs, Antibiotics (intermediates and bulk drugs), Vitamin C (bulk drugs) and Caffeine and Others (bulk drugs).

Receive News & Ratings for CSPC Pharmaceutical Group Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSPC Pharmaceutical Group Ltd and related companies with Analyst Ratings Network's FREE daily email newsletter.